# ClinicalTrials.gov record NCT00608023

> PeptideScanner retained ClinicalTrials.gov record NCT00608023 at 2026-07-30T19:35:26.307Z. Its registry update date was 2022-09-30, and PeptideScanner's reviewed identity mapping was tesamorelin.

- Evidence object: `story:clinicaltrials-gov-nct00608023-tesamorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-09-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00608023-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct00608023-tesamorelin-v1.json
- Content SHA-256: `8412bf1a86c5801918ca6d6c79f6271c30805238a8f8e8923f4a074e59ab9132`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT00608023 ([`ctg-observation-nct00608023-2022-09-30-87ed20b33e66`](#source-ctg-observation-nct00608023-2022-09-30-87ed20b33e66))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00608023 at 2026-07-30T19:35:26.307Z. Its registry update date was 2022-09-30, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct00608023-2022-09-30-87ed20b33e66`](#source-ctg-observation-nct00608023-2022-09-30-87ed20b33e66))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00608023 at 2026-07-30T19:35:26.307Z. Its registry update date was 2022-09-30, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct00608023-2022-09-30-87ed20b33e66`](#source-ctg-observation-nct00608023-2022-09-30-87ed20b33e66))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00608023-2022-09-30-87ed20b33e66`](#source-ctg-observation-nct00608023-2022-09-30-87ed20b33e66))

## Sources

<a id="source-ctg-observation-nct00608023-2022-09-30-87ed20b33e66"></a>
- **ClinicalTrials.gov record NCT00608023 · retained source version 2022-09-30:87ed20b33e66aadf1d77985e5901e20f0c57f8ddf6727384f4c070dea2968a2f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00608023) (`ctg-observation-nct00608023-2022-09-30-87ed20b33e66`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00608023." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct00608023-tesamorelin-v1.json SHA-256: 8412bf1a86c5801918ca6d6c79f6271c30805238a8f8e8923f4a074e59ab9132.